The study will be conducted in patients with metastatic colorectal cancer (mCRC) harboring a BRAFV600E mutation, to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with this pathology.
Despite substantial progress made in the first- and second line mCRC settings, there are still unmet clinical needs for patients harboring BRAFV600E mutations, especially those with microsatellite stability (MSS) / proficient mismatch repair (pMMR) tumor. The overall survival and access to different treatment in the real-life setting are unknown. Moreover, patient prognosis remains poor and therapeutic resistance to combinations with BRAF inhibitors, is at present, nearly universal. Therefore, it seems essential to prospectively collect clinical and biological data about this rare mCRC subtype. These data will allow us to improve knowledge and to identify clinical and biological factors that could drive therapeutic decisions, predict resistance to treatments, and that are prognostic for survival. In this context, we designed this large, prospective, cohort study to collect clinical data and biological samples to be used for research but also to gather real-world clinical data concerning the treatments and the survival outcomes in patients with BRAFV600E mCRC. This collection of clinical and biological data (tumor tissue and blood samples) will allow us to identify predictive and prognostic biomarkers with several research work packages planned: i. To evaluate the circulating tumor DNA (ctDNA) during the metastatic first-, second-, and third-line treatment to: * Evaluate its positive and negative predictive value. * Identify molecular alterations preceding and explaining clinical resistance during BRAF/EGFR inhibition therapy and immunotherapy. ii. To evaluate BRAFV600E mCRC immune environment both at the tumor and blood level (immunomonitoring). iii. To study specific the dMMR/MSI BRAFV600E subgroup. Furthermore, the data collected will describe the therapeutic management of BRAFV600E mCRC patients in the routine-practice setting which will bring very useful data. The results of the COBRAF study could lay the groundwork to better understand BRAFV600E mCRC and to identify prognostic and predictive biomarkers helping the development of new therapeutic approaches in this population.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
400
A 30 mL blood samples (6 mL in each of 5 EDTA tubes) will be collected from each patient at each timepoint.
Overall Survival (OS)
OS of patients with BRAFV600E mCRC in the real-life setting. The OS is defined as the time between the date of first diagnosis of mCRC and the date of death, whatever the cause. The patients alive at the time of analysis will be censored at the date of their last follow up.
Time frame: From date of first diagnosis of mCRC and the date of death, whatever the cause, up to 5 years
Collection of prospective data about BRAFV600E mCRC
Prospective collection of data collected during the normal clinical care. A descriptive analysis of the disease (Patients and tumors characteristics), current medical practices (molecular genotyping in France), and therapeutic sequences and composition of each treatment line (patients treated with immunotherapy, patients enrolled in clinical studies, metastatic surgeries). The resulting qualitative data analysis of the population will be expressed in number with percentage.
Time frame: Throughout study completion, up to 5 years
Correlation between prognostic markers and progression-free survival
PFS is defined as the length of time during and after the treatment of a disease that a patient lives with the disease but it does not get worse. PFS will then be correlated to clinical and biological prognostic markers analyzed at date of first diagnosis of mCRC and date of first progression or death by clinical testing used in routine cancer treatment practice (blood test analysis and tumor sample analysis). The Cox proportional-hazards model will then be used to study potential prognostic parameters PFS.
Time frame: From date of first diagnosis of mCRC and date of first progression or death, up to 5 years
Correlation between prognostic markers and overall survival
To identify clinical and biological prognostic markers of OS on blood and tumor samples. the OS is defined as the length of time from first diagnosis of mCRC that patients enrolled in the study are still alive. OS will then be correlated to clinical and biological prognostic markers analyzed at date of first diagnosis of mCRC and date of first progression or death by clinical testing used in routine cancer treatment practice (blood test analysis and tumor sample analysis). The Cox proportional-hazards model will then be used to study potential prognostic parameters OS.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Centre Hospitalier D'Avignon
Avignon, France
ACTIVE_NOT_RECRUITINGCentre Hospitalier de Bayeux
Bayeux, France
RECRUITINGChu Simone Veil
Beauvais, France
ACTIVE_NOT_RECRUITINGInstitut Bergonie
Bordeaux, France
RECRUITINGCH Fleyriat
Bourg-en-Bresse, France
ACTIVE_NOT_RECRUITINGCh de Cahors
Cahors, France
RECRUITINGCH Dr TECHER
Calais, France
ACTIVE_NOT_RECRUITINGInfirmerie Protestante de Lyon
Caluire-et-Cuire, France
ACTIVE_NOT_RECRUITINGChu Estaing de Clermont-Ferrand
Clermont-Ferrand, France
RECRUITINGGHPSO
Creil, France
RECRUITING...and 35 more locations
Time frame: Throughout study completion, up to 5 years
Objective response rate
The objective response rate (ORR) for each treatment line is defined as the percentage of patients with a complete response (CR) or a partial response (PR) for a given treatment line.
Time frame: From baseline to first disease progression, up to 5 years
Disease control rate
The disease control rate (DCR) is defined as the percentage of patients with a CR, a PR or stable disease for a given treatment line.
Time frame: From baseline to first disease progression, up to 5 years
Progression-free survival
The progression-free survival (PFS) for each treatment line is defined as the time interval between the start of treatment of the given line and the date of the first disease progression (radiological or clinical) or the start of another anticancer therapy, or death from any cause, whichever occurs first.
Time frame: From baseline to first disease progression, up to 5 years
ctDNA kinetics modeling outcome parameters
The detection of ctDNA level assessed by next generation sequencing in the blood of patients with deficient DNA mismatch repair (dMMR) / microsatellite instability (MSI) will be measured at the start of cycle 1, cycle 2, and cycle 3, and at 3 months and 6 months after starting each treatment line, as well as at disease progression. The level of ctDNA measured at each time point will provide information on how the body interacts with administered treatments overtime.
Time frame: From date of first diagnosis of mCRC until the date of first disease progression, up to 5 years
Correlation between predictive biomarkers and response to treatment
These biomarkers of response/resistance to combination treatment with anti-EGFR/anti-BRAF will be assessed by immunohistochemistry analysis of peripheral blood and tumor tissues.
Time frame: Throughout study completion, up to 5 years